(Q34990356)

5 August 2017

Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome (English)

1 reference

inflammatory breast cancer

5 August 2017

1 reference

1 reference

Wendy Woodward

5

0 references

Ana Maria Gonzalez-Angulo

8

object named as

Ana M Gonzalez-Angulo

1 reference

5 August 2017

9

Gabriel N Hortobagyi

1 reference

5 August 2017

Massimo Cristofanilli

10

object named as

Massimo Cristofanilli

1 reference

5 August 2017

Shaheenah Dawood

1

1 reference

5 August 2017

Yun Gong

2

1 reference

5 August 2017

Kristine Broglio

3

1 reference

5 August 2017

Thomas A Buchholz

4

1 reference

5 August 2017

Anthony Lucci

6

1 reference

5 August 2017

Vicente Valero

7

1 reference

5 August 2017

6 July 2010

1 reference

5 August 2017

1 reference

5 August 2017

16

1 reference

5 August 2017

5

1 reference

5 August 2017

529-532

1 reference

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Manipulating the chemokine-chemokine receptor network to treat cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Involvement of chemokine receptors in breast cancer metastasis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

The distribution of secondary growths in cancer of the breast. 1889

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097300

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20626396

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nuclear structure in cancer tissues

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20626396

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20626396

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1524-4741.2010.00953.X

1 reference

5 August 2017

1 reference

5 August 2017

1 reference